Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Street Poller Media and The Boom of the Street Interview Ad Industry 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Add as a preferred source on Google
SYDNEY, Australia and MINNEAPOLIS, April 12, 2018 -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, announces the completion of the acquisition of Vital Conversations.
Integrating Medibio’s objective mental health technology platform with Vital Conversations knowledge, experience and market position, has enabled the development of a unique comprehensive corporate health product. In addition to providing unique insights into individual and organizational mental health, Medibio is now equipped to work directly with corporations to improve health and performance.
Corporate Health SVP, Peta Slocombe, highlighted that, “objective measurements of mental health empowers organisations to better understand their individualised workforce above standard population information. This data empowers organisations to go beyond satisfactions surveys to identify which programs or initiatives are most effective.”
The acquisition expands Medibio’s presence across Australia and the United States. The Corporate Health business unit is actively engaged in securing contracts for products and services with multiple entry points tailored to organizational need. The new business unit will aim to reduce the burden of mental health conditions on individuals and organizations and to realize cost savings.
Jack Cosentino, CEO and Managing Director stated, “The ongoing support of our corporate advocates from Australia’s Biggest Mental Health Check-in have been an invaluable resource. We are positioned to lead in providing a measurable and objective methodology for improving employee mental health whilst driving a realizable 2x to 3x return on investment for corporations. As we secure contracts and commence launch of the product line over the upcoming months, we will update the market.”
As previously outlined the acquisition price of $500,000 was funded by cash and shares.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic), Perth (WA) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Stephanie Ottens Investor Relations Director Medibio Limited [email protected] T: +61 434 405 400 Australian Media Enquiries: Peter Taylor NWR Communications [email protected] T: +61 (0) 412 036 231
